ยาต้านการแข็งตัวของเลือดขนานใหม่
Article Sidebar
Main Article Content
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
References
Available at: http://www.who.int/whosis/mort/profiles/mort_searo_tha_thailand.pdf.
Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997; 337: 688–98.
Wells PS, Holbrook AM, Renee Crowther N, Hirsh J. Interactions of Warfarin with Drugs and Food. Ann Internal Med 1994; 121: 676-83.
Leung LLK. Anticoagulants other than heparin and warfarin. In: UpToDate, Basow, DS (Ed), UpToDate, Waltham, MA, 2009.
Ibbotson T, Perry CM. Danaparoid: a review of its use in thromboembolic and coagulation disorders. Drugs 2002; 62: 2283-314.
Salzet M. Leech thrombin inhibitors. Current Pharmaceutical Design 2002; 8: 125-33.
Di Nisio M, Middeldorp S, Bุ ller HR. Direct Thrombin Inhibitors. N Engl J Med 2005; 353: 1028-40.
Warkentin TE, Greinacher A, Koster A. Bivalirudin. Thromb Haemost 2008; 99: 830-9.
The van Gogh Investigators. Idraparinux versus standard therapy for venous thromboembolic disease. N Engl J Med 2007; 357: 1094-104.
Lassen MR, Gallus A, Raskob GE, Pineo G, Chen D, Ramirez LM. ADVANCE-3 Investigators. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Eng J Med 2010; 363: 2487-98.
Available at http://circ.ahajournals.org/cgi/content/abstract/CIRCULATIONAHA.109.924761 v1.